IDAI
T Stamp Inc.
Software - Application
Market Cap$3M
5Y Perf.-82.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IDAI vs ACXP
Revenue, margins, valuation, and 5-year total return — side by side.
ACXP
Acurx Pharmaceuticals, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-98.3%
IDAI vs ACXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IDAI | ACXP |
|---|---|---|
| Industry | Software - Application | Biotechnology |
| Market Cap | $3M | $5M |
| Revenue (TTM) | $4M | $0.00 |
| Net Income (TTM) | $-12M | $-7.97B |
| Gross Margin | 60.0% | — |
| Operating Margin | -183.3% | — |
| Total Debt | $4M | $0.00 |
| Cash & Equiv. | $3M | $7.56B |
IDAI vs ACXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IDAI
ACXP
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| T Stamp Inc. (IDAI) | 100 | 17.5 | -82.5% |
| Acurx Pharmaceutica… (ACXP) | 100 | 1.7 | -98.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IDAI vs ACXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IDAI leads in 3 of 4 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
IDAI
T Stamp Inc.
The Income Pick
IDAI carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.99
- 103.3% 10Y total return vs ACXP's -98.7%
- Lower volatility, beta 1.99, current ratio 1.12x
Best for: income & stability and long-term compounding
ACXP
Acurx Pharmaceuticals, Inc.
The Growth Play
ACXP is the clearest fit if your priority is growth exposure.
- EPS growth 69.8%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | IDAI | Beta 1.99 vs ACXP's 2.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IDAI | +22.0% vs ACXP's -69.4% |
| Efficiency (ROA) | IDAI | -105.4% ROA vs ACXP's -413.5% |
IDAI vs ACXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
IDAI vs ACXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACXPLAGGINGIDAI
IDAIT Stamp Inc.
2leads
ACXPAcurx Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs IDAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACXP1/1
Valuation MetricsMultiples, price ratios, and targets
ACXP2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACXP3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
IDAI4/6
Risk & VolatilityBeta, volatility, and downside exposure
IDAI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACXP leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IDAI and ACXP operate at a comparable scale, with $4M and $0 in trailing revenue.
| Metric | IDAIT Stamp Inc. | ACXPAcurx Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $4M | $0 |
| EBITDAEarnings before interest/tax | -$6M | $35,910 |
| Net IncomeAfter-tax profit | -$12M | -$8.0B |
| Free Cash FlowCash after capex | -$8M | $4.6B |
| Gross MarginGross profit ÷ Revenue | +60.0% | — |
| Operating MarginEBIT ÷ Revenue | -183.3% | — |
| Net MarginNet income ÷ Revenue | -3.2% | — |
| FCF MarginFCF ÷ Revenue | -2.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +70.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +32.1% | +98.2% |
ACXP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ACXP leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | IDAIT Stamp Inc. | ACXPAcurx Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $3M | $5M |
| Enterprise ValueMkt cap + debt − cash | $4M | -$7.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.22x | -0.39x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.90x | — |
| Price / BookPrice ÷ Book value/share | 0.87x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
ACXP leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ACXP leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
IDAI delivers a -189.5% return on equity — every $100 of shareholder capital generates $-190 in annual profit, vs $-6 for ACXP. On the Piotroski fundamental quality scale (0–9), ACXP scores 3/9 vs IDAI's 1/9, reflecting mixed financial health.
| Metric | IDAIT Stamp Inc. | ACXPAcurx Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -189.5% | -6.0% |
| ROA (TTM)Return on assets | -105.4% | -4.1% |
| ROICReturn on invested capital | -2.2% | — |
| ROCEReturn on capital employed | -194.9% | — |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 1.30x | — |
| Net DebtTotal debt minus cash | $1M | -$7.6B |
| Cash & Equiv.Liquid assets | $3M | $7.6B |
| Total DebtShort + long-term debt | $4M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -22.08x | — |
ACXP leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
IDAI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACXP five years ago would be worth $132 today (with dividends reinvested), compared to $89 for IDAI. Over the past 12 months, IDAI leads with a +22.0% total return vs ACXP's -69.4%. The 3-year compound annual growth rate (CAGR) favors IDAI at -50.0% vs ACXP's -67.6% — a key indicator of consistent wealth creation.
| Metric | IDAIT Stamp Inc. | ACXPAcurx Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -38.1% | -24.3% |
| 1-Year ReturnPast 12 months | +22.0% | -69.4% |
| 3-Year ReturnCumulative with dividends | -87.5% | -96.6% |
| 5-Year ReturnCumulative with dividends | -99.1% | -98.7% |
| 10-Year ReturnCumulative with dividends | +103.3% | -98.7% |
| CAGR (3Y)Annualised 3-year return | -50.0% | -67.6% |
IDAI leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
IDAI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IDAI is the less volatile stock with a 1.99 beta — it tends to amplify market swings less than ACXP's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IDAI currently trades 47.3% from its 52-week high vs ACXP's 10.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IDAIT Stamp Inc. | ACXPAcurx Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.99x | 2.42x |
| 52-Week HighHighest price in past year | $5.28 | $21.00 |
| 52-Week LowLowest price in past year | $1.80 | $1.33 |
| % of 52W HighCurrent price vs 52-week peak | +47.3% | +10.0% |
| RSI (14)Momentum oscillator 0–100 | 52.7 | 38.0 |
| Avg Volume (50D)Average daily shares traded | 44K | 3.6M |
IDAI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | IDAIT Stamp Inc. | ACXPAcurx Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.1% | +100.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACXP leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). IDAI leads in 2 (Total Returns, Risk & Volatility).
Best OverallAcurx Pharmaceuticals, Inc. (ACXP)Leads 3 of 6 categories
Loading custom metrics...
IDAI vs ACXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — IDAI or ACXP?
Over the past 5 years, Acurx Pharmaceuticals, Inc.
(ACXP) delivered a total return of -98. 7%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: IDAI returned +102. 4% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — IDAI or ACXP?
By beta (market sensitivity over 5 years), T Stamp Inc.
(IDAI) is the lower-risk stock at 1. 99β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 21% more volatile than IDAI relative to the S&P 500.
03Which is growing faster — IDAI or ACXP?
On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc.
grew EPS 69. 8% year-over-year, compared to 29. 3% for T Stamp Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — IDAI or ACXP?
Acurx Pharmaceuticals, Inc.
(ACXP) is the more profitable company, earning 0. 0% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACXP leads at 0. 0% versus -303. 9% for IDAI. At the gross margin level — before operating expenses — IDAI leads at 65. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IDAI or ACXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IDAI or ACXP better for a retirement portfolio?
For long-horizon retirement investors, T Stamp Inc.
(IDAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+102. 4% 10Y return). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDAI: +102. 4%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IDAI and ACXP?
These companies operate in different sectors (IDAI (Technology) and ACXP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.